Co-Diagnostics, Inc. to Present at the Fourth Annual Robins Equity Research Roundup

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics
company with a unique, proprietary platform for the development of
molecular diagnostic tests, announced today that it will be presenting
at the Fourth Annual Robins Equity Research Roundup, held September 25 –
26, 2018 near Portland, Oregon.

The Equity Research Roundup is sponsored by Catalyst Research Management
Group, RIA, to offer opportunities for portfolio, hedge, and mutual fund
managers, individual investors, and retail brokers to become acquainted
with up-and-coming public and private companies. In addition to company
presentations from a range of industries, the conference will also
facilitate company introductions to influential members of the
investment community. Co-Diagnostics CEO Dwight Egan will be presenting
at 10:30 AM PDT on September 25th.

Mr. Egan remarked: “We are excited to return to the Equity Research
Roundup and to share the progress we have made since our presentation a
year ago. We believe that Marc Robins’ experience advocating for public
micro-cap companies and experience in bringing them together with
notable members of the investment world will facilitate telling our
story to that community.”

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics
company that develops, manufactures and markets a new, state-of-the-art
diagnostics technology. The Company’s technology is utilized for tests
that are designed using the detection and/or analysis of nucleic acid
molecules (DNA or RNA). The Company also uses its proprietary technology
to design specific tests to locate genetic markers for use in industries
other than infectious disease and license the use of those tests to
specific customers.

Forward-Looking Statements:

This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
“believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will”
and similar expressions, or the negative of these words. Such
forward-looking statements are based on facts and conditions as they
exist at the time such statements are made and predictions as to future
facts and conditions. Forward-looking statements in this release
include statements regarding the (i) use of funding proceeds, (ii)
expansion of product distribution, (iii) acceleration of initiatives in
liquid biopsy and SNP detection, (iv) use of the Company’s liquid biopsy
tests by laboratories, (v) capital resources and runway needed to
advance the Company’s products and markets, (vi) increased sales in the
near-term, (vii) flexibility in managing the Company’s balance sheet,
(viii) anticipation of business expansion, and (ix) benefits in research
and worldwide accessibility of the CoPrimer technology and its
cost-saving and scientific advantages. Forward-looking statements are
subject to inherent uncertainties, risks and changes in circumstances.
Actual results may differ materially from those contemplated or
anticipated by such forward-looking statements. Readers of this press
release are cautioned not to place undue reliance on any forward-looking
statements. The Company does not undertake any obligation to update any
forward-looking statement relating to matters discussed in this press
release, except as may be required by applicable securities laws.

Contacts

Company Contact:
Co-Diagnostics Investor Relations
Andrew
Benson, 801-438-1036
investors@codiagnostics.com
or
Investor
Contact:
Lytham Partners, LLC
Joe Diaz, Robert Blum and
Joe Dorame
602-889-9700